Tamoxifen decreases drug efflux from liposomes: Relevance to its ability to reverse multidrug resistance in cancer cells?
Explore this paper's citation graph
Summary
The possible importance of the ability of tamoxifen to inhibit drug efflux from liposomes in relation to its ability to reverse multidrug resistance in cancer patients caused by the efflux of cytotoxic therapeutic agents, is discussed.
- Type
- article
- Published
- 1994-05-16
- Cited by
- 34
- References
- 28
- Access
- Open access
- OpenAlex
- https://openalex.org/W2020216724
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:43725543
Keywords
Efflux, Multiple drug resistance, Tamoxifen, Drug resistance, Liposome
References
- The structural mimicry of membrane sterols by tamoxifen: evidence from cholesterol coefficients and molecular-modelling for its action as a membrane anti-oxidant and an anti-cancer agent.
- How safe is tamoxifen?
- Adjuvant tamoxifen versus placebo in elderly women with node-positive breast cancer: long-term follow-up and causes of death.
- Liposomes : a practical approach
- Tamoxifen and related compounds decrease membrane fluidity in liposomes
- Tamoxifen: new membrane-mediated mechanisms of action and therapeutic advances.
- Selective reversal of vinblastine resistance in multidrug-resistant cell lines by tamoxifen, toremifene and their metabolites.
- Clinical and radiographic response in a minority of patients with recurrent malignant gliomas treated with high-dose tamoxifen.
- Tamoxifen: molecular basis of use in cancer treatment and prevention
- High-dose tamoxifen as an enhancer of etoposide cytotoxicity. Clinical effects and in vitro assessment in p-glycoprotein expressing cell lines.
- High-dose (480 mg/day) tamoxifen with etoposide: a study of a potential multi-drug resistance modulator.
- Results of the Cancer Research Campaign Adjuvant Trial for Perioperative Cyclophosphamide and Long-Term Tamoxifen in Early Breast Cancer reported at the tenth year of follow-up. Cancer Research Campaign Breast Cancer Trials Group.
- Breast cancer chemoprevention tamoxifen: Current issues and future prospective
- The treatment of intracranial malignant gliomas using orally administered tamoxifen therapy: preliminary results in a series of "failed" patients.
- The case for clinical trials of tamoxifen for prevention of breast cancer.
- Induction of Transforming Growth Factor β1 in Human Breast Cancer in Vivo following Tamoxifen Treatment
- Effect of tamoxifen on the multidrug-resistant phenotype in human breast cancer cells: isobologram, drug accumulation, and M(r) 170,000 glycoprotein (gp170) binding studies.
- High-dose oral tamoxifen, a potential multidrug-resistance-reversal agent: phase I trial in combination with vinblastine.
- Reduction of the membrane fluidity of human breast cancer cells by tamoxifen and 17 beta-estradiol.
- Clinical trial of tamoxifen in patients with irresectable pancreatic adenocarcinoma
Cited by
- PTD modified paclitaxel anti-resistant liposomes for treatment of drug-resistant non-small cell lung cancer
- Tamoxifen inhibits nitrobenzylthioinosine-sensitive equilibrative uridine transport in human MCF-7 breast cancer cells.
- Multifunctional targeting daunorubicin plus quinacrine liposomes, modified by wheat germ agglutinin and tamoxifen, for treating brain glioma and glioma stem cells
- A dual-targeting nanocarrier based on poly(amidoamine) dendrimers conjugated with transferrin and tamoxifen for treating brain gliomas.
- Investigation of the influence of modulation of P-glycoprotein by a multiple dosing regimen of tamoxifen on the pharmacokinetics and toxicodynamics of doxorubicin
- Phase II study of tamoxifen, ifosfamide, epirubicin and cisplatin combination chemotherapy in patients with non-small cell lung cancer failing previous chemotherapy.
- The liposomal daunorubicin plus tamoxifen: improving the stability, uptake, and biodistribution of carriers
- The antipsychotic drug chlorpromazine enhances the cytotoxic effect of tamoxifen in tamoxifen-sensitive and tamoxifen-resistant human breast cancer cells
- Advances in investigations on the mechanism of cancer multidrug resistance and the liposomes-based treatment strategy
- Enhanced efficacy of functionalized epirubicin liposomes in treating brain glioma-bearing rats.
- Tamoxifen inhibits uptake and metabolism of ethanolamine and choline in multidrug‐resistant, but not in drug‐sensitive, MCF‐7 human breast carcinoma cells
- Applications of dendrimers for brain delivery and cancer therapy.
- Concentration dependency of modulatory effect of amlodipine on P‐glycoprotein efflux activity of doxorubicin — a comparison with tamoxifen
- Liposomal formulations of cytotoxic drugs
- Interactions of tamoxifen with distearoyl phosphatidylcholine multilamellar vesicles: FTIR and DSC studies.
- Tamoxifen alters dopamine output through direct actions upon superfused corpus striatal tissue fragments.
- Gemcitabine and tamoxifen-loaded liposomes as multidrug carriers for the treatment of breast cancer diseases.
- Quantitative comparison of the inhibitory effects of GW5638 and tamoxifen on angiogenesis in the cornea pocket assay
- Dietary influences on membrane function : importance in protection against oxidative damage and disease
- Tamoxifen embedded in lipid bilayer improves the oncotarget of liposomal daunorubicin in vivo.
Related papers
- Efflux Pumps of Mycobacterium tuberculosis Play a Significant Role in Antituberculosis Activity of Potential Drug Candidates
- A genetic platform to investigate the functions of bacterial drug efflux pumps
- Antimicrobial Resistance: Two-Component Regulatory Systems and Multidrug Efflux Pumps
- The role of RND-type efflux pumps in multidrug-resistant mutants of Klebsiella pneumoniae
- Function and Inhibitory Mechanisms of Multidrug Efflux Pumps
- Drug Efflux Pump Inhibitors: A Promising Approach to Counter Multidrug Resistance in Gram-Negative Pathogens by Targeting AcrB Protein from AcrAB-TolC Multidrug Efflux Pump from Escherichia coli
- Study on eleven efflux pump genes in multidrug-resistant Escherichia coli